Enveda key facts
as of Oct 2026- Developer of a drug analysis platform designed to capitalize on the chemical diversity and evolutionary significance of natural samples.
- Enveda is valued at approximately $2.0B as of Oct 2026, set at its Series E, Sep 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $530.0M across 1 recorded rounds; the latest was Series E ($311.0M) in Sep 2026.
- Notable investors include Lightspeed Venture Partners, Gaingels, Lux Capital, Village Global, True Ventures — 47 tracked in total.
- Status: Privately Held (backing).
Valued at $2.0B at its Series E, Sep 2026. Nothing has traded since.
- ·The post-money valuation on its round
- ·The complete investor list: 47 names
- ·Watch Enveda: the Monday email on marks, rounds and moves
Enveda funding rounds
1 roundsWho backs Enveda
47+Enveda valuation
Enveda was valued at $2 billion at its Series E in Sep 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Enveda's record added 1 funding round.
How much has Enveda raised?
Enveda has raised $530 million in total; 1 of its rounds is on record. The largest on record was a $311 million Series E in Sep 2026. 1 of the rounds disclosed a post-money valuation.
Enveda investors
47 investors are on record for Enveda, including Lightspeed Venture Partners, Gaingels, Lux Capital and Village Global. By type, the record holds 13 venture capital firms, 3 hedge funds and 3 growth equity firms. The Series E in Sep 2026 drew 16 investors.
About Enveda
Developer of a drug analysis platform designed to capitalize on the chemical diversity and evolutionary significance of natural samples. The company's platform offers a combination of machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, enabling clients in the healthcare industry to identify and characterize a wide range of molecules produced by living organisms without isolating individual compounds or conducting extensive experimentation.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2019
- Employees
- 325
- Website
- enveda.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.